XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investment in Rafael Pharmaceuticals (Details) - USD ($)
shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Oct. 01, 2021
Jan. 31, 2019
Sep. 24, 2021
Jan. 28, 2021
Jan. 31, 2022
Jan. 31, 2022
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Ownership percentage in non-operating subsidiary           50.00%
Principal amount   $ 10.0        
Total impairment loss           $ 17.3
Noncontrolling interests         $ 79.1 79.1
Interest amount           $ 10.4
Rafael Pharmaceuticals [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Ownership percentage in non-operating subsidiary           90.00%
Fully diluted         10.00% 10.00%
Percentage of outstanding capital stock           51.00%
Percentage of outstanding capital stock on fully diluted basis           41.00%
Impairment charge of approximately           $ 79.1
CS Pharma Holdings, LLC [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Ownership percentage in subsidiary and holds percentage of interest           50.00%
Indirect interest in assets held, percentage           45.00%
Fully diluted         10.00% 10.00%
Convertible promissory note, rate of interest   3.50%        
Pharma Holdings [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Ownership percentage in non-operating subsidiary           90.00%
Exercise price of warrants or rights, description           The Company currently owns 51% of the issued and outstanding equity in Rafael Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant, which is non-dilutable and provides for the Company to increase its (via Pharma Holdings and CS Pharma and inclusive of the interests held by the other owners of those entities) total ownership to 56%. Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of July 31, 2021, the Company, and the Company’s affiliates, would need to pay approximately $17 million to exercise the Warrant in full to 56%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company and the Company’s affiliates would need to pay approximately $126 million to exercise the Warrant in full (including to offset the impact of additional issuances of Rafael Pharmaceuticals equity under the Line of Credit, as defined below). The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant.
Exercise of warrants purchases, description       On January 28, 2021, Pharma Holdings partially exercised the Warrant to maintain the 51% ownership percentage and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.     
Aggregate amount     $ 25.0      
Agreement accrues interest per annum     9.00%      
Reserve amount           $ 25.0
Credit agreement amount         $ 0.6  
Other amounts           1.5
Related party interest receivable         $ 0.6 0.8
CS Pharma and Pharma Holdings [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Interest amount           $ 6.9
First Advance [Member] | Pharma Holdings [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Advance amount of debtor     $ 1.9      
Second Advance [Member] | Pharma Holdings [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Advance amount of debtor $ 23.1          
Howard Jonas [Member] | Rafael Pharmaceuticals [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Fully diluted         10.00% 10.00%
Series D Convertible Preferred Stock [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Exercise of warrants purchases, description           The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the Board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up Rafael Pharmaceuticals, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. 
Series D Convertible Preferred Stock [Member] | CS Pharma Holdings, LLC [Member]            
Investment in Rafael Pharmaceuticals (Details) [Line Items]            
Exercise price of warrants or rights, description           Pharma Holdings holds 44.0 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. 
Purchase of exercise the warrant, shares (in Shares)           16.7